Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296530 · ClinicalTrials.gov registry record · Phase 4
Study Of Patients With Allergic Rhinitis And Asthma
A Phase 4 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00296530 is a Phase 4 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 600 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00296530, a Phase 4 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
Conditions Studied
Interventions
- DRUG montelukast
- DRUG fluticasone propionate
- DRUG fluticasone propionate/salmeterol
Study Locations (20)
California
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Orange
- GSK Investigational Site - Palmdale
- GSK Investigational Site - Riverside
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Jose
- GSK Investigational Site - Stockton
- GSK Investigational Site - Vista
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Denver
- GSK Investigational Site - Denver
- GSK Investigational Site - Wheat Ridge
Florida
- GSK Investigational Site - Coral Gables
- GSK Investigational Site - Miami
Alabama
- GSK Investigational Site - Ozark
Arizona
- GSK Investigational Site - Tempe
Arkansas
- GSK Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296530
The ClinicalTrials.gov registry entry for NCT00296530 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (62% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which montelukast is the first listed.
NCT00296530 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00296530 about?
NCT00296530 is a clinical study titled "Study Of Patients With Allergic Rhinitis And Asthma". This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs u...
What is the current status of trial NCT00296530?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2005-09. Estimated completion is 2007-07.
What conditions does trial NCT00296530 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00296530?
The interventions under investigation include: montelukast (DRUG), fluticasone propionate (DRUG), fluticasone propionate/salmeterol (DRUG).
Who is sponsoring clinical trial NCT00296530?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00296530 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.